BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...
BioCentury | Dec 8, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million on Dec. 7 in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

...eligible for 1% of net sales. Galactosialidosis is caused by mutations in the gene encoding cathepsin A...
...St. Jude researchers published data in The FASEB Journal in 2004 showing treatment with recombinant cathepsin A...
BioCentury | Dec 7, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed investors. Lumicell said...
BioCentury | Oct 10, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A panel of 17 genomic loci could help predict the risk of PD. Genome-wide association studies in a total of 20,084 PD patients and 397,324 healthy volunteers identified associations between the disease...
BioCentury | Sep 29, 2017
Clinical News

Medivir reports Phase IIa data of MIV-711 for OA

Medivir AB (SSE:MVIR B) reported top-line data showing that MIV-711 slowed the degenerative effects of moderate osteoarthritis (OA) on both bone and cartilage of the knee in the Phase IIa MIV-711-201 trial. The company said...
BioCentury | Sep 26, 2017
Clinical News

Medivir rises on Phase IIa OA data

Medivir AB (SSE:MVIR B) gained SEK14.75 (25%) to SEK74.75 on Tuesday after reporting that MIV-711 slowed the degenerative effects of moderate osteoarthritis on both bone and cartilage of the knee in the Phase IIa MIV-711-201...
Items per page:
1 - 10 of 178